

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Role of brain neuroactive steroids in the functional interplay between the GABA(A) and the NPY-Y1 receptor mediated signals in the amygdala**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/38111> since

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

# Role of brain neuroactive steroids in the functional interplay between the GABA<sub>A</sub> and the NPY-Y<sub>1</sub> receptor mediated signals in the amygdala

Carola Eva<sup>a,\*</sup>, Alessandra Oberto<sup>a</sup>, Paolo Mele<sup>a</sup>, Mariangela Serra<sup>b</sup>, Giovanni Biggio<sup>b</sup>

<sup>a</sup> *Dipartimento di Anatomia, Farmacologia e Medicina Legale, Sezione di Farmacologia, Via Pietro Giuria 13, 10125, Università di Torino, Torino, Italy*

<sup>b</sup> *Dipartimento di Biologia Sperimentale, Sezione di Neuroscienze, Università di Cagliari, Cagliari, Italy*

Available online 5 July 2006

## Abstract

Various lines of evidence suggest a functional interaction between GABA<sub>A</sub> and Neuropeptide Y (NPY)-Y<sub>1</sub> receptor (Y<sub>1</sub>R) mediated transmissions in various brain regions, which can be important in the regulation of sedation, feeding, anxious behaviour and neuronal excitability. By using a transgenic mouse model carrying the murine Y<sub>1</sub>R gene promoter fused to the *lacZ* reporter gene (*Y<sub>1</sub>R/LacZ* mice), we showed that prolonged pharmacologically or physiologically induced changes in the cerebrocortical concentrations of the neuroactive steroids 3alpha-hydroxy-5alpha-pregnan-20-one (3alpha,5alpha TH PROG) and tetrahydrodeoxycorticosterone (3alpha,5alpha TH DOC) increases *Y<sub>1</sub>R/LacZ* transgene expression in the central and medial amygdala, an effect similar to that induced by long-term treatment with positive modulators of the GABA<sub>A</sub> receptor complex (diazepam or abecarnil). We also demonstrated that fluctuations in the cerebrocortical concentrations of 3alpha,5alpha-TH PROG and 3alpha,5alpha TH DOC during voluntary ethanol consumption and ethanol withdrawal induces a marked increase in Y<sub>1</sub>R gene expression that becomes apparent 48 h after withdrawal.

These data provide evidence that neuroactive steroids may play an important role in the functional interaction between the GABA<sub>A</sub> receptor and NPY-Y<sub>1</sub>R mediated pathways in the amygdala, which might represent an important regulatory mechanism for modulation of several functions, including ethanol withdrawal.

© 2006 Elsevier Inc. All rights reserved.

**Keywords:** GABA; Neuroactive steroids; Neuropeptide Y; Y<sub>1</sub> receptors; Pregnancy; Ethanol; Stress; Amygdala; Transgenic mice

## 1. Introduction

Neuropeptide Y (NPY)<sup>1</sup> is one of the most abundant and widely distributed peptides in the central nervous system that belongs, together with the peptide YY (PYY) and the pancreatic polypeptide (PP), to the family of pancreatic peptides (Tatemoto et al., 1982). Immunohistochemical and *in situ* hybridization studies have shown that NPY is abundantly expressed in various brain regions of rodents and humans, including the cerebral cortex, amygdala, hypothalamus, hippocampus, locus coeruleus and nucleus accumbens (Allen et al., 1983; Chronwall et al., 1985; de

Quidt and Emson, 1986; Dumont et al., 1992; Chronwall and Zukowska, 2004). In the brain, NPY participates in the regulation of several physiological functions that include emotional behaviour and stress response, neuronal excitability, feeding behaviour and energy homeostasis, ethanol consumption, learning and memory, GnRH secretion, sexual behaviour and circadian rhythms (Kalra and Crowley, 1992; Wahlestedt and Reis, 1993; Colmers and Bleakman, 1994; Baraban et al., 1997; Hokfelt et al., 1998; Vezzani et al., 1999).

NPY interacts with at least five different G-protein coupled receptors named Y<sub>1</sub>, Y<sub>2</sub>, Y<sub>4</sub>, Y<sub>5</sub>, and y<sub>6</sub> subtypes (Blomqvist and Herzog, 1997; Michel et al., 1998). The Y<sub>1</sub> receptor (Y<sub>1</sub>R), Y<sub>2</sub> receptor and Y<sub>5</sub> receptor bind preferentially to NPY and PYY whereas PP is the preferring ligand for the Y<sub>4</sub> receptor (Lundell et al., 1995; Rose et al., 1995; Gerald et al., 1996; Weinberg et al., 1996). Since the y<sub>6</sub> receptor protein is truncated in most mammals and it is functional only in mouse and rabbit, its biological relevance remains to be clarified (Starback et al., 2000).

*Abbreviations:* NPY, neuropeptide Y; Y<sub>1</sub>R, Y<sub>1</sub> receptor; GABA,  $\gamma$ -aminobutyric acid; GABA<sub>A</sub>, GABA type A receptor; 3alpha,5alpha TH PROG, 3alpha-hydroxy-5alpha-pregnan-20-one; 3alpha,5alpha TH DOC, tetrahydrodeoxycorticosterone; MeA, medial amygdala; CeA, central amygdala; ARC, arcuate nucleus; PVN, paraventricular nucleus; IR, immunoreactive.

\* Corresponding author. Tel.: +39 011 6707718; fax: +39 011 6707788.

E-mail address: [carola.eva@unito.it](mailto:carola.eva@unito.it) (C. Eva).

The Y<sub>1</sub>R subtype for NPY was the first NPY receptor to be cloned in the rat by us (Eva et al., 1990; Krause et al., 1992) and subsequently in human (Herzog et al., 1992) and mouse (Eva et al., 1992). Sequence analysis of mammalian and non-mammalian Y<sub>1</sub>R demonstrated that it displays a high sequence homology in the transmembrane regions and it is highly conserved throughout evolution (Larhammar and Salaneck, 2004). Y<sub>1</sub>R is coupled to the inhibition of adenylate cyclase, by the activation of a pertussis toxin sensitive GTP binding protein Gi/Go, and to the mobilization of Ca<sup>2+</sup> from intracellular stores (Herzog et al., 1992). Moreover, Y<sub>1</sub>R stimulates the mitogen activated protein kinase (MAPK) pathways, via extracellularly regulated kinase (ERK) phosphorylation, an effect that has been shown to be dependent on PI-3-kinase (Nie and Selbie, 1998; Mannon and Mele, 2000).

The distribution of Y<sub>1</sub>R within the mammalian CNS was extensively analyzed using receptor autoradiography, immunohistochemistry and *in situ* hybridization. By using receptor autoradiography Y<sub>1</sub>R-binding sites were found in the cerebral cortex, olfactory nuclei, dentate gyrus, thalamus, septum, cerebellum and in the paraventricular (PVN) and dorsomedial hypothalamic nuclei (Dumont et al., 1998). More recent studies in rat and mouse, using specific cRNA probes and *in situ* hybridization techniques, detected a larger amount of Y<sub>1</sub>R mRNA positive neurons, in particular in the thalamus, in the limbic system (hippocampus, amygdala and bed nucleus of the stria terminalis) and in the hypothalamus (medial preoptic area, PVN, dorsomedial, ventromedial and arcuate (ARC) hypothalamic nuclei) (Kishi et al., 2005). The lack of localization of Y<sub>1</sub>R mRNA with NPY mRNA observed in the human brain suggests that the Y<sub>1</sub>R is mainly located postsynaptically (Caberlotto et al., 2000). However the presence of Y<sub>1</sub>R has been identified in NPY-IR neurons in the nucleus accumbens, medial amygdala (MeA) and rat hippocampus suggesting that the Y<sub>1</sub>R may also act as a presynaptic receptor (St-Pierre et al., 1998, 2000; Pickel et al., 1998; Oberto et al., 2001).

The physiological importance of the Y<sub>1</sub>R was first discovered by pharmacological studies using selective agonists and antagonists showing high binding affinities for this receptor subtype. The functional contributions of Y<sub>1</sub>R to a particular physiological process have also been provided by studies on genetically modified mice lacking the Y<sub>1</sub>R subtype (Pedrazzini et al., 1998; Kushi et al., 1998; Kanatani et al., 2000; Naveilhan et al., 2001b; Howell et al., 2003) as well as by studies showing dynamic changes of this receptor subtype in response to different conditions, for instance stress and anxiety, convulsions or changes in feeding behaviour (Eva et al., submitted for publication).

In the brain, the Y<sub>1</sub>R subtype has been involved in several NPY-induced responses, such as the anxiolytic effects and stress response (Broqua et al., 1995; Heilig, 1995; Sajdyk et al., 2004), ethanol drinking behaviour (Thiele et al., 2002; Schroeder et al., 2003; Thiele and Badia-Elder, 2003; Sparta et al., 2004), stimulation of food intake (Kask et al., 1998; Kanatani et al., 2000; Wisialowski et al., 2000; Mullins et al., 2001) and activation of neuroendocrine axis (Kalra et al., 1992; Besecke et al., 1994). Moreover, different lines of evidence have shown that Y<sub>1</sub>R plays a permissive role in seizures (Gariboldi et al., 1998; Vezzani et al., 2000, 2002; Benmaamar et al., 2003).

## 2. NPY and $\gamma$ -aminobutyric acid (GABA)

NPY has similar properties to those observed with positive modulators of the GABA type A (GABA<sub>A</sub>) receptor complex, like benzodiazepines and neuroactive steroids, on sleep (Heilig and Murison, 1987; Yamada et al., 1996; Ehlers et al., 1997), anxiety, stress (Heilig et al., 1989, 1992; Broqua et al., 1995; Sajdyk et al., 1999; Bannon et al., 2000; Thorsell et al., 2000; Kask et al., 2001), convulsions (Mikkelsen et al., 1994; Erickson et al., 1996; Baraban et al., 1997; Woldbye et al., 1997; Bolwig et al., 1999), as well as feeding behaviour (Cowley et al., 2001; Pronchuk et al., 2002; cuna-Goycolea et al., 2005; Sato et al., 2005). Various lines of evidence suggest a functional interaction between GABA and NPY that can be important in the regulation of sedation, feeding, anxious behaviour and neuronal excitability (Kask et al., 1996; Oberto et al., 2000, 2002; Ferrara et al., 2001; Mikkelsen et al., 2001; Ovesjo et al., 2001; Zhang and Wang, 2005). For instance, GABA is coexpressed with NPY/Agouti-Related Protein in ARC neurons (Horvath et al., 1997; Pu et al., 1999) projecting into the PVN where they act synergistically to inhibit Corticotropin Releasing Factor neurons and to enhance feeding (Hahn et al., 1998; Broberger et al., 1998a,b; Pu et al., 1999). Moreover GABA is co-released from NPY/Agouti-Related Protein neurons in the ARC where it was shown to inhibit Proopiomelanocortin neurons by acting through different receptors (Horvath et al., 1997; Pu et al., 1999; Cowley et al., 2001).

Anatomical and functional evidence also suggests an interplay between hypothalamic GABAergic neurons and NPY (Pu et al., 1999; Cowley et al., 2001; Horvath et al., 2001; Pronchuk et al., 2002) in the regulation of both fertility and food intake (Kalra et al., 1991; Catzefflis et al., 1993; Glass et al., 1999; Raposinho et al., 2001). In particular, NPY has been suggested to inhibit fertility by decreasing the activity of GABAergic neurons afferent to Gonadotropin Releasing Hormone neurons, an effect that appears to be mediated via the NPY-Y<sub>1</sub>R subtype (Sullivan and Moenter, 2004).

In the hippocampus and neocortex, NPY is made by neurons that almost all express GABA (Pu et al., 1999; Jinno and Kosaka, 2003). Results from several studies have indicated that neocortical and hippocampal neurons coexpressing NPY and GABA might be involved in the response to epileptogenesis. In the neocortex, NPY was found to increase GABAergic neurotransmission onto pyramidal neurons and to decrease inhibition on GABAergic interneurons (Bacci et al., 2002). Each of these NPY actions decreases excitability in cortical circuits, resulting in the potentiation of NPY and GABA inhibitory responses. NPY/GABA interneurons in the hippocampus are selectively ablated in rat epilepsy models *in vivo* (Sloviter, 1989, 1991) and in epileptic patients (de Lanerolle et al., 1989).

A functional interaction between the GABAergic and NPY-Y<sub>1</sub>R mediated transmissions in the regulation of emotional behaviour was first demonstrated by Kask et al. (1996) that showed that the anxiolytic benzodiazepine diazepam blocks the anxiogenic effect of Y<sub>1</sub>R antagonists. NPY was also reported to induce sedative effects through the GABAergic system by interacting with the Y<sub>1</sub>R in the posterior hypothalamus (Naveilhan et al., 2001a).

On the other hand, modulation of GABA<sub>A</sub> receptor complex induces changes in the expression of NPY and NPY mRNA in various brain region. Acute, sub-chronic and chronic treatments with benzodiazepines affects the NPY immunoreactivity in the amygdala, cerebral cortex and locus coeruleus and hypothalamus in naive rats (Krysiak et al., 1999) and in rats with conditioned fear produced in the passive avoidance test (Krysiak et al., 2000), although these changes were dependent on the type of treatment and on the different brain nuclei. In addition, long-term treatment with flurazepam induces a decrease of NPY immunoreactivity in the hippocampus of tolerant and dependent rats that is associated with the decrease of Y<sub>1</sub>R mRNA expression in tolerant rats but not during withdrawal (Zhang and Wang, 2005).

Moreover, intrahippocampal administration of antisense oligonucleotides against the GABA<sub>A</sub> receptor  $\gamma$ 2 subunit, that induces spontaneous electrographic hippocampal seizures and elevates seizure threshold induced by electrical stimulation, increases NPY mRNA and receptor protein in the hippocampal region. (Mikkelsen et al., 2001). This induction of NPY has been suggested to be a part of compensatory mechanism acting in response to a reduction in functional hippocampal postsynaptic GABA<sub>A</sub> receptors.

By using a *Y<sub>1</sub>R/LacZ* transgenic mouse model, we extensively investigated the functional interaction between GABAergic and NPY-Y<sub>1</sub>R mediated transmission in the amygdala. We here summarize the results of several studies from our laboratory suggesting that changes in GABA<sub>A</sub> receptor function, induced by various pharmacological and physiological conditions, may affect NPY-Y<sub>1</sub>R signal transmission by modulating the gene expression of the Y<sub>1</sub>R subtype in the MeA and in the central amygdala (CeA).

### 3. The *Y<sub>1</sub>R/LacZ* transgenic mouse model

We generated a transgenic mouse line (*Y<sub>1</sub>R/LacZ* mice) bearing the 1.3 Kb 5' flanking region of the murine Y<sub>1</sub>R gene promoter linked to the coding region of the *Escherichia coli LacZ* gene (Oberto et al., 1998). Analysis of *Y<sub>1</sub>R/LacZ* transgene activity by histochemical staining of  $\beta$ -galactosidase with X-gal demonstrated that this construct contains sufficient information to replicate the expression pattern of the endogenous Y<sub>1</sub>R gene in a CNS-restricted and developmental stage-specific manner. Four transgenic lines showed characteristic patterns of  $\beta$ -galactosidase activity in specific brain regions; moreover, the ontogenetic analysis indicated that the transgenic construct appears to be activated with the same timing of the endogenous Y<sub>1</sub>R during the development of the embryonic nervous system.

The advantages of this transgenic model are that  $\beta$ -galactosidase staining with chromogenic substrate X-gal is more sensitive and more readily quantifiable than mRNA *in situ* hybridization and it can be usefully employed to quantitatively evaluate *in vivo* changes in transgene expression.

To study *in vivo* the regulation of Y<sub>1</sub>R gene expression at the transcriptional level we employed computer-assisted morphometrical techniques to quantitatively evaluate changes in *Y<sub>1</sub>R/LacZ* transgene expression by automatically quantifying the number of dye precipitates within a selected region, (Russ,

1995). These calculations allow a numerical measurement which is proportional to the histochemical activity of the expressed transgene and are extremely useful for statistical comparison of different treatments.

By using this approach, we have shown that chronic modulation of GABA<sub>A</sub> receptor function regulates Y<sub>1</sub>R gene expression in the amygdala of *Y<sub>1</sub>R/LacZ* transgenic mice. Furthermore we demonstrated that *Y<sub>1</sub>R/LacZ* transgene expression in the CeA and MeA can be also modulated in response to a long-lasting increase in the cerebrocortical concentrations of neuroactive steroids induced by various pharmacological and physiological conditions.

### 4. Morphological evidence of a functional interplay between the GABAergic and NPY-Y<sub>1</sub>R systems in the MeA

Using immunolabelling for NPY and GABA and histochemical staining of *Y<sub>1</sub>R/LacZ* transgene expression we provided morphological evidence for a functional interaction between GABA and NPY-Y<sub>1</sub>R mediated transmission in the MeA (Fig. 1) (Oberto et al., 2001). The confocal analysis of GABA and NPY-immunoreactive (IR) neurons in brain coronal sections from *Y<sub>1</sub>R/LacZ* transgenic mice has shown that in the MeA the majority of NPY-IR cell bodies were positive for GABA and that, in some cases, GABA and NPY coexist within the same nerve fibers. Moreover, the simultaneous detection of  $\beta$ -galactosidase histochemical staining and of GABA and NPY immunostaining revealed a high degree of colocalization for GABA or NPY and the *Y<sub>1</sub>R/LacZ* transgene. GABA-IR neurons coexpressing  $\beta$ -galactosidase histochemical staining were usually in close contact with NPY-IR fibers that were surrounding or covering the cell bodies, suggesting that NPY neurons innervate GABAergic neurons that also express the Y<sub>1</sub>R gene and that NPY might inhibit GABA release by the activation of this receptor subtype. Few NPY-IR cell bodies also showed the  $\beta$ -galactosidase histochemical staining suggesting that the Y<sub>1</sub>R may also act as an auto-receptor in this brain area. On the other hand, several GABA-IR elements, that do not display  $\beta$ -galactosidase positive staining, are surrounded by NPY positive fibers, indicating that not all GABAergic neurons are regulated by Y<sub>1</sub>R. These findings could account for a complex response to NPY in the MeA and suggest that the interconnectivity between the NPY-Y<sub>1</sub>R-mediated transmission and the GABAergic system may be an important regulatory mechanism within the MeA and may contribute to the effects of NPY on anxious behaviour.

### 5. Chronic modulation of GABA<sub>A</sub> receptor function regulates Y<sub>1</sub>R gene expression in the amygdala

To provide functional evidence for interplay between GABA and NPY systems within the amygdala we first analyzed the effect of modulation of GABA<sub>A</sub> receptor complex on Y<sub>1</sub>R gene expression in the MeA of *Y<sub>1</sub>R/LacZ* transgenic mice.

Positive allosteric modulators of GABA receptor complex, such benzodiazepines, enhance GABA<sub>A</sub> receptor function and produce sedative, anxiolytic and anticonvulsant effects on behaviour (Costa et al., 1975; Haefely, 1986; Costa and Guidotti,



1996). Conversely negative allosteric modulators of the GABA<sub>A</sub> receptor complex, such as  $\beta$ -carbolines FG 7142, inhibit GABA-gated Cl<sup>-</sup> channels and elicit anxiogenic and proconvulsant activity (Dorow et al., 1983). Chronic administration of diazepam and other agonists of the benzodiazepine binding site decreases GABA<sub>A</sub> receptor function whereas repeated administration of  $\beta$ -carbolines increases sensitivity to its proconvulsant activity (Corda et al., 1985; Woods et al., 1992). These behavioural and

physiological effects are associated with changes in the expression of GABA<sub>A</sub> receptor subunits mRNA (Chen et al., 1999).

We demonstrated that the prolonged treatment with positive (diazepam and abecarnil) or negative modulators (FG7142) of GABA<sub>A</sub> receptor function induces, respectively, a significant increase, or decrease, of the Y<sub>1</sub>R gene expression in the MeA. These findings are consistent with the hypothesis that, in the amygdala, the NPY-Y<sub>1</sub> receptor-mediated transmission and




Fig. 1. Confocal images illustrating the coexistence and close relationships among NPY, GABA, and Y<sub>1</sub>R/LacZ expressing elements. In green the immunolabelling for NPY, in red the immunolabelling for GABA, in dark blue the histochemical staining for  $\beta$ -galactosidase. Yellow cells or fibers are elements where NPY (green) and GABA (red) coexist. A–F: confocal images obtained merging several focus planes. Bar in A represents 30  $\mu$ m. G, H: single, not merged confocal images. Bar in G represents 30  $\mu$ m. In A and C, the arrow points to the same fiber recognisable for its characteristic shape showing NPY (A) and GABA (C) immunoreactivity. The same fiber is stained in yellow in B. In D and F the arrows point to numerous co-existent NPY- and GABA-immunoreactive cell bodies which are yellow in E. In G and H the arrowheads indicate a few of the numerous elements showing also the histochemical staining for  $\beta$ -galactosidase. In H the arrow point to NPY-positive cell bodies showing also  $\beta$ -galactosidase activity. The asterisk indicates one yellow cell body positive for  $\beta$ -galactosidase. The same cell is clearly identifiable in E (asterisk), the image reconstructed from the series to which H is belonging. Reprinted from Oberto et al., *Neuropharmacology* 2001;41: 639–642, with permission from Elsevier. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

GABA-ergic system are closely coupled and that NPY and GABA may functionally interact in the regulation of anxiety behaviour (Kask et al., 1996). The molecular mechanisms that underlie changes in *Y<sub>1</sub>R/LacZ* transgene expression induced by prolonged administration with ligands of the BZ/ $\omega$  binding site remain to be determined. Given that the NPY-*Y<sub>1</sub>R* mediated transmission elicits behavioural effects that are indistinguishable from those induced by the activation of GABA<sub>A</sub> receptors (Heilig et al., 1989, 1992; Broqua et al., 1995; Sajdyk et al., 1999; Bannon et al., 2000; Thorsell et al., 2000; Kask et al., 2001) and that GABA and NPY coexist within the same neurons in the amygdala (Gustafson et al., 1986; McDonald and Pearson, 1989; Oberto et al., 2001), it is possible that changes in the function of GABA<sub>A</sub> receptors elicit compensatory responses in the firing rate of NPY-containing neurons which, in turn, might be responsible of changes in *Y<sub>1</sub>* receptor gene transcriptional activity.

## 6. Role of neuroactive steroids in modulation of NPY-*Y<sub>1</sub>R* transmission in the amygdala

### 6.1. Effects of a sustained increase in brain concentrations of neuroactive steroids on *Y<sub>1</sub>R* gene expression

The 5- $\alpha$ -reduced progesterone (PROG) metabolites, 3 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-20-one (3 $\alpha$ ,5 $\alpha$  TH PROG) and tetrahydrodeoxycorticosterone (3 $\alpha$ ,5 $\alpha$  TH DOC), are endogenous neuroactive steroids, which affect the excitability of central neurons in a manner independent of nuclear hormone receptors (Biggio and Purdy, 2001). These compounds are among the most potent positive allosteric modulators of the GABA<sub>A</sub> receptor complex (Majewska et al., 1986; Belelli and Lambert, 2005). Thus, their acute administration in pharmacological doses potentiate the GABA<sub>A</sub> receptor function and elicit anxiolytic, anticonvulsant and hypnotic/anesthetic effects similar to those produced by other positive allosteric modulators of GABA<sub>A</sub> receptors (Lambert et al., 2001; Rupprecht et al., 2001). In particular, the anxiolytic action of 3 $\alpha$ ,5 $\alpha$  TH PROG has been demonstrated in various animal models of anxiety and the amygdaloid complex has recently been implicated as a brain region that plays an important role in mediating the anxiolytic action of 3 $\alpha$ ,5 $\alpha$  TH PROG (Akwa et al., 1999).

Fluctuations in plasma or brain concentrations of 3 $\alpha$ ,5 $\alpha$  TH PROG, occurring in association with specific physiological and pathological conditions, such as stress, pregnancy, the menstrual cycle, menopause, regulation of neuronal excitability, and a variety of neurological or psychiatric disorders (Barbaccia et al., 1996; Bicikova et al., 1998; Concas et al., 1998; Genazzani et al., 1998; Biggio and Purdy, 2001) result in changes in neuronal excitability and, in turn, in alteration of emotional state, sleep pattern, and seizure threshold (Guidotti and Costa, 1998; Engel and Grant, 2001; Wang et al., 2001). Moreover, physiological or pharmacologically induced changes in the levels of 3 $\alpha$ ,5 $\alpha$ -TH PROG are associated, at the molecular level, with changes in the expression of GABA<sub>A</sub> receptor subunits (Biggio and Purdy, 2001; Biggio et al., 2001; Smith and Gong, 2004). Given that 3 $\alpha$ ,5 $\alpha$  TH PROG and 3 $\alpha$ ,5 $\alpha$  TH DOC are among the most potent positive modulators of GABA<sub>A</sub> receptor




Fig. 2. Effects of long-term treatment with progesterone on the concentrations of progesterone (A), AP (B), and THDOC (C) in the cerebral cortex of *Y<sub>1</sub>R/LacZ* transgenic mice. Mice were treated with vehicle (VEH), progesterone (P), or progesterone plus finasteride (P+F) according to the 3-week, single-injection, multiple-withdrawal paradigm, as previously described (Moran and Smith, 1998). They were killed 20 min (P20, P20+F), 90 min (VEH, P90, P90+F), or 24 h (PW, PW+F) after the last injection (W indicates withdrawal), and the concentrations of 41 progesterone, AP, and THDOC in cerebrocortical homogenates were determined. Data are means  $\pm$  SEM of values from 3 to 8 mice and are expressed as nanograms of steroid per gram of protein. Progesterone, \* $p$  < 0.01 versus VEH, \*\* $p$  < 0.05 versus P20; AP, \* $p$  < 0.05 versus VEH, \*\* $p$  < 0.01 versus P90; THDOC, \* $p$  < 0.05 versus VEH, P90, PW, and PW+F (Newman–Keuls test). Reproduced from Ferrara et al., *J. Neurochem.* 2001;79: 417–425 with permission of Blackwell Publishing.






Fig. 3. Effect of long-term treatment with progesterone on  $Y_1R/LacZ$  transgene expression in the medial amygdala. Progesterone treatment was performed as described in Fig. 2. Histochemical staining of  $\beta$ -galactosidase activity in coronal sections of the medial amygdala 90 min after the last injection is shown for mice treated with vehicle (A) or with progesterone (5 mg/kg, i.p.) (B), as well as for mice that received a single daily subcutaneous injection of finasteride (25 mg/kg) during the last week of treatment with progesterone (C). Scale bar, 100  $\mu$ m. Reproduced from Ferrara et al., J. Neurochem. 2001;79: 417–425 with permission of Blackwell Publishing.

function known, we investigated whether fluctuation in the brain concentrations of these neuroactive steroids might also affect  $Y_1R$  gene expression in the amygdala.

Chronic treatment with progesterone or with 3 $\alpha$ ,5 $\alpha$  TH PROG induces a significant augmentation of the cerebrocortical concentration of 3 $\alpha$ ,5 $\alpha$  TH PROG and 3 $\alpha$ ,5 $\alpha$  TH DOC (Fig. 2) that is associated with an increase in the expression of the  $Y_1R/LacZ$  transgene in the MeA

similar to that elicited by long-term administration of abecarnil or diazepam (Figs. 3A,B, 4) (Ferrara et al., 2001).

In addition, physiological fluctuations in the cerebrocortical concentrations of endogenous 3 $\alpha$ ,5 $\alpha$  TH PROG and 3 $\alpha$ ,5 $\alpha$  TH DOC during pregnancy (Table 1) are also associated with increased  $Y_1R/LacZ$  transgene expression in the MeA (Figs. 5A,B, 6) (Oberto et al., 2002). The levels of  $Y_1R$  mRNA in the MeA were also increased on day 18 of pregnancy, suggesting that changes in transgene expression reflect parallel changes in the endogenous  $Y_1R$  gene that are achieved, at least in part, via transcriptional mechanisms (Fig. 7). The increase in the  $Y_1R$  gene expression in the MeA induced by chronic treatment with progesterone or by physiological conditions, such as pregnancy, is likely to be mediated by 3 $\alpha$ ,5 $\alpha$  TH PROG and 3 $\alpha$ ,5 $\alpha$  TH DOC through their selective action at the GABA<sub>A</sub> receptor. In fact, pretreatment of  $Y_1R/LacZ$  transgenic mice with the 5 $\alpha$ -reductase inhibitor finasteride, which inhibits the biosynthesis of 3 $\alpha$ ,5 $\alpha$  TH PROG and




Fig. 4. Quantitation of  $Y_1R/LacZ$  transgene expression in the medial amygdala of mice subjected to long-term treatment with progesterone or AP. (A) Mice were subjected to prolonged treatment with vehicle (VEH), with progesterone (P), or with progesterone and finasteride (P+F) as described in Fig. 2, and were killed 90 min (VEH, P, P+F) or 24 h (PW, PW+F) after the last injection (W indicates withdrawal). Coronal sections of the medial amygdala were subjected to quantitative analysis of  $\beta$ -galactosidase histochemical staining. Data are expressed as the density of blue dots and are means  $\pm$  SEM of values from 5 to 15 mice. \* $p$  < 0.01 versus VEH, PW, and P+F groups (Newman–Keuls test). (B) Mice were treated for 10 days with vehicle or AP (5 mg/kg, i.p.) and were killed 90 min (VEH, AP) or 24 h (APW) after the last injection. Data were analyzed as in (A) and are means  $\pm$  SEM of values from 5 to 10 mice. \* $p$  < 0.01, \*\* $p$  < 0.05 versus VEH (Newman–Keuls test). Reproduced from Ferrara et al., J. Neurochem. 2001;79: 417–425 with permission of Blackwell Publishing.

Table 1

Effects of finasteride treatment on the concentrations of progesterone, AP, and THDOC in the cerebral cortex of estrus and pregnant mice

	Steroid (ng/g)		
	Progesterone	AP	THDOC
Estrus	15.8 $\pm$ 1.7	11.6 $\pm$ 0.8	3.6 $\pm$ 0.5
Estrus + finasteride	16.5 $\pm$ 3.0	9.4 $\pm$ 1.4	3.9 $\pm$ 0.1
Pregnant	39.8 $\pm$ 2.8*	24.2 $\pm$ 2.2**	9.9 $\pm$ 1.3**
Pregnant + finasteride	39.9 $\pm$ 3.9*	15.8 $\pm$ 1.9	4.5 $\pm$ 0.4

Mice were treated with vehicle or finasteride (25 mg/kg, s.c.) from day 12 to day 17 of pregnancy and killed on day 18. Estrus mice were similarly treated with finasteride or vehicle for 6 days. Data are means  $\pm$  SEM of values from 4 to 10 mice and are expressed as nanograms of steroid per gram of cortical tissue. \* $p$  < 0.01 versus estrus and estrus + finasteride; \*\* $p$  < 0.01 versus estrus, estrus + finasteride, and pregnant + finasteride (Newman–Keuls test). Reproduced from Oberto et al., J. Neurochem. 2002;82: 1272–1281, with permission of Blackwell Publishing.




Fig. 5. Effects of pregnancy and delivery on  $Y_1R/LacZ$  transgene expression in the medial amygdala. Coronal sections of the medial amygdala of mice in estrus (A), on day 18 of pregnancy in the absence (B) or presence (C) of finasteride treatment (25 mg/kg, s.c. from day 12 to day 17), or on day 2 after delivery (D) were subjected to histochemical staining for  $\beta$ -galactosidase activity. Scale bar, 100  $\mu$ m. Reproduced from Oberto et al., *J. Neurochem.* 2002;82: 1272–1281, with permission of Blackwell Publishing.

3 $\alpha$ ,5 $\alpha$  TH DOC (Azzolina et al., 1997), prevented both the accumulation of 3 $\alpha$ ,5 $\alpha$  TH PROG and 3 $\alpha$ ,5 $\alpha$  TH DOC in the cerebral cortex as well as the increase in  $Y_1R/LacZ$  gene expression in the amygdala (Ferrara et al., 2001; Oberto et al., 2002). These findings therefore suggest that the high concentrations achieved by neuroactive steroids in the cerebral cortex of mice following chronic treatment with progesterone or during pregnancy might play a major role in modulation of both GABA<sub>A</sub> and  $Y_1R$  mediated transmissions.

Fluctuation in the levels of brain 3 $\alpha$ ,5 $\alpha$ -TH PROG are associated with alterations of the subunit composition of the GABA<sub>A</sub> receptor as well as of GABA<sub>A</sub> receptor function (Biggio and Purdy, 2001; Biggio et al., 2001; Smith and Gong, 2004; Follesa et al., 2005; Serra et al., 2006); these changes might, in turn, produce adaptive responses in the NPY-mediated transmission and  $Y_1R$  gene expression. Indeed, the reduction in the brain concentrations of these steroids elicited either by a physiological condition (delivery) or by pharmacological treatment (finasteride) reversed or prevented both the increase in  $Y_1R/LacZ$  transgene expression (Ferrara et al., 2001; Oberto et al., 2002) as well as changes in the expression of GABA<sub>A</sub> receptor subunit genes (Biggio et al., 2001). The rapid decrease in the 3 $\alpha$ ,5 $\alpha$  TH PROG and 3 $\alpha$ ,5 $\alpha$  TH DOC cerebrocortical concentra-

tions, following discontinuation of chronic progesterone administration (Fig. 2) as well as following delivery, induce withdrawal effects at the behavioural and molecular levels that are highly similar to those elicited by discontinuation of long-term treatment with positive allosteric modulators of GABA<sub>A</sub> receptor such as benzodiazepines (Follesa et al., 1998, 2001). However, the increase of  $Y_1R/LacZ$  transgene expression in the MeA was no longer apparent 24 h after the last hormone injection, or after delivery, indicating that changes in NPY- $Y_1R$  signal do not play a role in progesterone-induced withdrawal syndrome (Figs. 4, 5D, 6A).

#### 6.2. Effects of chronic voluntary alcohol consumption and ethanol withdrawal on $Y_1R$ gene expression in the amygdala

Ethanol exerts anxiolytic, sedative/hypnotic, anticonvulsant, and muscle relaxant effects similar to those induced by different modulators of the GABA<sub>A</sub> receptor such as benzodiazepines, barbiturates, and neuroactive steroids (Brot et al., 1995; Grobin et al., 1998; Koob et al., 1998; VanDoren et al., 2000). Behavioural, neurochemical, and electrophysiological evidences indicate that GABA<sub>A</sub> receptors are indeed targets for the acute as well as chronic actions of ethanol. The acute action of ethanol is characterized by a facilitation of GABA<sub>A</sub> receptor function, whereas, on the contrary, its chronic exposure is associated to a diminished sensitivity to GABA, benzodiazepines and barbiturates, and to an enhanced sensitivity to neuroactive steroids and to the inverse agonists at the benzodiazepine receptors  $\beta$ -carboline (Mhatre




Fig. 6. Quantitation of  $Y_1R/LacZ$  transgene expression in the medial amygdala of mice during pregnancy and after delivery. (A) Coronal sections of the medial amygdala were subjected to quantitative analysis of  $\beta$ -galactosidase histochemical staining. Values are shown for mice in estrus (E), on day 18 of pregnancy (P18), and on days 2 (PD2) and 7 (PD7) after delivery. Data are expressed as the density of blue dots and are means  $\pm$  SEM of values from 5 to 9 mice. \* $p$  < 0.01 versus E, PD2, and PD7 (Newman–Keuls test). (B) Pregnant mice were injected daily with vehicle or finasteride (25 mg/kg, s.c.) from day 12 to day 17 and then killed on day 18 (P18 and P18+F, respectively). Estrus mice were similarly treated with vehicle (VEH) or with finasteride (F) for 6 days. Coronal sections of the medial 43 amygdala were then analyzed for  $\beta$ -galactosidase activity as in (A). Data are means  $\pm$  SEM of values from 5 to 10 mice. \* $p$  < 0.01 versus VEH, F, and P18+F (Newman–Keuls test). Reproduced from Oberto et al., *J. Neurochem.* 2002;82: 1272–1281, with permission of Blackwell Publishing.






Fig. 7. Effects of pregnancy on  $Y_1$  receptor mRNA expression in the medial amygdala. Low power magnification of an autoradiogram illustrating the neuroanatomical distribution of  $Y_1$  receptor mRNA visualized by *in situ* hybridization on a coronal brain section from an estrous female mice (A). Scale bar, 1 mm. High power magnification of autoradiograms showing the right medial amygdala of female mice in estrus (B) and on day 18 of pregnancy (C). Original sections were hybridized with four oligonucleotide probes and exposed to X-ray film for 8 days. The figure is representative of results obtained from 4 to 6 mice in each group. Scale bar, 0.5 mm. Reproduced from Oberto et al., *J. Neurochem.* 2002;82: 1272–1281, with permission of Blackwell Publishing.

et al., 1988; Sanna et al., 1993; Becker and Jarvis, 1996; Devaud et al., 1996).

Moreover, long-term administration of ethanol and ethanol withdrawal elicit neurochemical and molecular effects similar to those induced by positive modulators of  $GABA_A$  receptor function (Morrow et al., 1990; Mhatre et al., 1993; Devaud et al., 1997; Biggio et al., 2003). In particular, chronic ethanol administration differentially alters the expression of distinct  $GABA_A$  receptor subunit mRNA and peptides in various brain regions (Mhatre and Ticku, 1992; Devaud et al., 1997; Sanna et al., 2003; Follesa et al., 2005; Olsen et al., 2005).

In addition to a direct action at the  $GABA_A$  receptor, the acute action of ethanol at  $GABA_A$  receptors was proposed to be mediated by neuroactive steroids produced in peripheral organs, or by peripheral precursors that are converted to neurosteroids by brain cells (Morrow et al., 1999). Acute ethanol administration increases the concentrations of allopregnanolone in the plasma, cerebral cortex, and hippocampus (Barbaccia et al., 1999; VanDoren et al., 2000; Morrow et al., 2001; Serra et al., 2003). Furthermore, pretreatment of animals with the  $5\alpha$ -reductase inhibitor finasteride, reduced the ethanol-induced increase in the cerebrocortical concentrations of  $3\alpha,5\alpha$  TH PROG and prevented certain molecular, neurochemical, electrophysiological, and behavioural effects of ethanol (VanDoren et al., 2000; Khisti et al., 2002).

NPY is also involved with neurobiological responses to ethanol (Thiele and Badia-Elder, 2003; Pandey, 2003; Koob,

2003; Thiele et al., 2004). Voluntary alcohol consumption and resistance to the intoxicating effects of ethanol are inversely related to NPY levels in knockout and transgenic mice. NPY knockout mice consume significantly higher amounts of ethanol than do wild type strains, whereas transgenic mice over expressing NPY have a lower preference for ethanol than wild type mice (Thiele et al., 1998). Chronic ethanol administration and ethanol withdrawal also influence NPY signalling, although the effect of ethanol on NPY may vary with the duration and type of ethanol treatment, rodent strain and brain region. For instance, both investigator- and self-administered ethanol increases NPY levels in the hypothalamic structures and in ventrolateral medulla of Long Evans rats (Clark et al., 1998) whereas no differences in NPY protein content were observed in several brain regions of Wistar rats following 7 week exposure to ethanol vapours (Ehlers et al., 1998) or in Sprague Dawley rats fed for 15 days with ethanol diet (Roy and Pandey, 2002). Conversely, NPY immunoreactivity and NPY mRNA were shown to be decreased by single or repeated administrations of intoxicating doses of ethanol in distinct brain regions of rodents, including the hypothalamus, hippocampus and cerebral cortex (Kinoshita et al., 2000; Roy and Pandey, 2002; Bison and Crews, 2003).

On the other hand, consistent results have found that NPY levels and mRNA are significantly decreased 24 h after withdrawal in some brain regions involved in seizure activity and anxious behaviour, including CeA, MeA, cerebral cortex and hippocampus (Roy and Pandey, 2002; Zhang and Pandey, 2003; Bison and Crews, 2003), suggesting that a reduced activity of NPY neurons may represent one of the mechanisms implicated in ethanol withdrawal symptoms. This decrease is followed by a dramatic increase of NPY expression in the hippocampus that occurs 72 h after withdrawal which was suggested to represent a protective response against prolonged withdrawal seizure activity (Ehlers et al., 1998; Bison and Crews, 2003).

We demonstrated that  $Y_1R$  gene expression in the MeA and CeA of  $Y_1R/LacZ$  transgenic mice was not affected by voluntary alcohol consumption for 4 weeks, but it significantly increased 48 h following ethanol withdrawal (Mele et al., submitted for publication). This finding suggests the possibility that the decrease of NPY levels in the amygdaloid structures, that is associated with the behavioural manifestations of ethanol withdrawal, may induce the up-regulation of the  $Y_1R$  subtype.

To determine whether the increased biosynthesis of  $3\alpha,5\alpha$  TH PROG induced by ethanol was responsible for its effect on  $Y_1R$  gene transcriptional activity we analyzed the effect of pretreatment with finasteride of  $Y_1R/LacZ$  transgenic mice on  $\beta$ -galactosidase expression in the CeA and MeA. Our findings demonstrated that finasteride administration prevented both the ethanol-induced increase of  $3\alpha,5\alpha$  TH PROG in the cerebral cortex as well as the increase of  $Y_1R/LacZ$  gene expression in the amygdala induced by 24 h ethanol withdrawal in the amygdala (Mele et al., submitted for publication). These findings suggest that the ability of ethanol withdrawal to affect the NPY- $Y_1R$  signal transmission involves fluctuation of brain concentrations of  $3\alpha,5\alpha$  TH PROG and may possibly depend on changes of  $GABA_A$  receptor function and subunit composition that occur during ethanol consumption and ethanol

withdrawal. Indeed, in addition to preventing the increase in  $Y_1R/LacZ$  transgene expression induced by ethanol withdrawal, finasteride pretreatment reduces ethanol withdrawal severity (Finn et al., 2004; Gorin et al., 2005).

### 6.3. Effect of a transient increase of cerebrocortical concentrations of neuroactive steroids on $Y_1R$ gene expression in the amygdala of $Y_1R/LacZ$ transgenic mice?

NPY and GABA may also interact to inhibit the excitatory effects of CRF in the amygdala and thereby contribute to the overall response to stressful or threatening stimuli (Heilig et al., 1994). Several acute stress paradigms, such as forced swimming, foot shock, and carbon dioxide inhalation, reduce GABA<sub>A</sub> receptor function in several brain regions, induce proconflict behavior (Corda and Biggio, 1986) and increase the concentrations of neuroactive steroids in plasma and the brain to levels that are high enough to activate GABA<sub>A</sub> receptors (Purdy et al., 1991; Barbaccia et al., 1996, 1997, 2001; Reddy and Rogawski, 2002). The rapid and persistent increase in neuroactive steroid concentrations induced by acute stress has been proposed to represent a homeostatic mechanism for the restoration of GABA<sub>A</sub> receptor function and to be physiologically relevant in protection against stress-induced seizures. On the other hand, short-term physical restraint, which induces anxiety, reduces NPY mRNA and protein concentrations in the amygdala and cortex of rats (Thorsell et al., 1998). In contrast, repeated exposure to restraint once daily for 10 days increases NPY expression in the amygdala and in the ARC (Thorsell et al., 1999).

Given that the sustained increase of cerebrocortical concentrations of neuroactive steroids that occurs during pregnancy or long-term administration of progesterone affect both GABA<sub>A</sub> receptor and  $Y_1R$  gene expression (Concas et al., 1998; Follesa et al., 1998; Ferrara et al., 2001; Oberto et al., 2002), we have examined the hypothesis that a rapid increase in the plasma and brain content of these compounds might also participate in the regulation of  $Y_1R$  plasticity in response to restraint stress.

Acute exposure to restraint induced a transient increase in the cerebrocortical concentrations of neuroactive steroids that returns to control values within 30 min. Acute restraint also increased  $Y_1R/LacZ$  transgene expression in the CeA and in the MeA of transgenic mice (Mele et al., 2004). Finasteride prevented the transient increase in the cerebrocortical concentrations of 3alpha,5alpha-TH PROG and 3alpha,5alpha-TH DOC, but failed to inhibit that in  $Y_1R$  gene expression in the amygdala of the stressed mice. Moreover, repeated exposure to restraint, that induces repetitive and transient elevation in the concentrations of neuroactive steroids in the cerebral cortex, failed to affect  $Y_1R$  gene (Mele et al., 2004). These findings, taken together, indicate that changes in the brain concentrations of neuroactive steroids and in  $Y_1R$  gene expression induced by restraint stress are achieved independently of each other and suggest that a sustained increase in the brain concentrations of these steroids may be required for modulation of  $Y_1R$  gene expression.

Accordingly, the exposure to 5 min foot shock stress as well as the acute treatment with ethanol, both of which transiently increase the concentrations of 3alpha,5alpha-TH PROG in the cerebral cortex, failed to affect  $Y_1R$  in transgenic mice (unpublished results).

## 7. Conclusions

Results reviewed above indicate that chronic administration of various modulators of the GABA<sub>A</sub> receptor complex as well as prolonged pharmacologically or physiologically induced changes in 3alpha,5alpha-TH PROG concentrations affect  $Y_1R$  gene expression in the MeA and CeA.

Molecular, physiological and neurochemical evidence demonstrated that long term exposure to these modulators triggers cellular adaptive mechanisms that involve alteration in the subunit composition of the GABA<sub>A</sub> receptor with regional differences which, in turn, might affect receptor function and altered pharmacological and behavioural sensitivity (Follesa et al., 2000, 2001, 2002).

Given the important role of the GABA/NPY interaction in regulation of several functions, including emotional behaviour and neuronal excitability, these findings suggest that altered GABA receptor function might trigger compensatory changes on NPY-containing neurons that, in turn, might be responsible of up-regulation of  $Y_1R$  gene. This hypothesis is supported by the observation that chronic treatment with benzodiazepines modulates the expression of NPY and NPY mRNA in various brain regions (Krysiak et al., 1999, 2000). Furthermore the decrease of GABA<sub>A</sub> receptor  $\gamma 2$  subunit expression induced by the administration of antisense oligonucleotides is associated with a profound increase of NPY mRNA and receptor protein expression in rat hippocampus (Mikkelsen et al., 2001).

On the other hand, we have shown that fluctuations in the cerebrocortical concentration of 3alpha,5alpha-TH PROG during voluntary ethanol consumption and ethanol withdrawal induces a marked increase in  $Y_1$  receptor gene expression that becomes apparent 48 h after withdrawal. This observation suggests that the increase of brain neuroactive steroid concentrations induced by voluntary ethanol consumption might produce changes on GABA<sub>A</sub> receptor function different from those induced by progesterone treatment or pregnancy. In this regard, ethanol has been shown to increase brain steroidogenesis by a local action independently on the activity of the hypothalamic-pituitary-adrenal axis (Sanna et al., 2004). Given the diversity and heterogeneity of GABA<sub>A</sub> receptor expressed in different neurons the ethanol-induced changes in the expression of each subunit might differently affect the NPY- $Y_1$  pathway.

## References

- Akwa Y, Purdy RH, Koob GF, Britton KT. The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. *Behav Brain Res* 1999;106:119–25.
- Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, et al. Neuropeptide Y distribution in the rat brain. *Science* 1983;221:877–9.
- Azzolina B, Ellsworth K, Andersson S, Geissler W, Bull HG, Harris GS. Inhibition of rat alphaeductases by finasteride: evidence for isozyme

- differences in the mechanism of inhibition. *J Steroid Biochem Mol Biol* 1997;61:55–64.
- Bacci A, Huguenard JR, Prince DA. Differential modulation of synaptic transmission by neuropeptide Y in rat neocortical neurons. *Proc Natl Acad Sci U S A* 2002;99:17125–30.
- Bannon AW, Seda J, Carmouche M, Francis JM, Norman MH, Karbon B, et al. Behavioral characterization of neuropeptide Y knockout mice. *Brain Res* 2000;868:79–87.
- Baraban SC, Hloppeter G, Erickson JC, Schwartzkroin PA, Palmiter RD. Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. *J Neurosci* 1997;17:8927–36.
- Barbaccia ML, Roscetti G, Bolacchi F, Concas A, Mostallino MC, Purdy RH, et al. Stress-induced increase in brain neuroactive steroids: antagonism by abecarnil. *Pharmacol Biochem Behav* 1996;54:205–10.
- Barbaccia ML, Roscetti G, Trabucchi M, Purdy RH, Mostallino MC, Concas A, et al. The effects of inhibitors of GABAergic transmission and stress on brain and plasma allopregnanolone concentrations. *Br J Pharmacol* 1997;120:1582–8.
- Barbaccia ML, Africano D, Trabucchi M, Purdy RH, Colombo G, Agabio R, et al. Ethanol markedly increases “GABAergic” neurosteroids in alcohol-preferring rats. *Eur J Pharmacol* 1999;384: R1–R2.
- Barbaccia ML, Serra M, Purdy RH, Biggio G. Stress and neuroactive steroids. *Int Rev Neurobiol* 2001;46:243–72.
- Becker HC, Jarvis MF. Chronic ethanol exposure selectively increases diazepam-insensitive [3H]RO15-4513 binding in mouse cerebellum. *Eur J Pharmacol* 1996;296:43–6.
- Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABA(A) receptor. *Nat Rev Neurosci* 2005;6:565–75.
- Benmaamar R, Pham-Le BT, Marescaux C, Pedrazzini T, Depaulis A. Induced down-regulation of neuropeptide Y-Y1 receptors delays initiation of kindling. *Eur J Neurosci* 2003;18:768–74.
- Besecke LM, Wolfe AM, Pierce ME, Takahashi JS, Levine JE. Neuropeptide Y stimulates luteinizing hormone-releasing hormone release from superfused hypothalamic GT1-7 cells. *Endocrinology* 1994;135:1621–7.
- Bicikova M, Dibbelt L, Hill M, Hampl R, Starka L. Allopregnanolone in women with premenstrual syndrome. *Horm Metab Res* 1998;30:227–30.
- Biggio G, Purdy RH. Neurosteroids and brain function. In: Bradley RJ, Harris RA, Jenner P, editors. *International review of neurobiology Academic*; 2001.
- Biggio G, Follesa P, Sanna E, Purdy RH, Concas A. GABAA-receptor plasticity during long-term exposure to and withdrawal from progesterone. *Int Rev Neurobiol* 2001;46:207–41.
- Biggio G, Dazzi L, Biggio F, Mancuso L, Talani G, Busonero F, et al. Molecular mechanisms of tolerance to and withdrawal of GABA(A) receptor modulators. *Eur Neuropsychopharmacol* 2003;13:411–23.
- Bison S, Crews F. Alcohol withdrawal increases neuropeptide Y immunoreactivity in rat brain. *Alcohol Clin Exp Res* 2003;27:1173–83.
- Blomqvist AG, Herzog H. Y-receptor subtypes — how many more? *Trends Neurosci* 1997;20:294–8.
- Bolwig TG, Woldbye DP, Mikkelsen JD. Electroconvulsive therapy as an anticonvulsant: a possible role of neuropeptide Y (NPY). *J ECT* 1999;15:93–101.
- Broberger C, de LL, Sutcliffe JG, Hokfelt T. Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems. *J Comp Neurol* 1998a;402:460–74.
- Broberger C, Johansen J, Johansson C, Schalling M, Hokfelt T. The neuropeptide Y/agouti generated protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. *Proc Natl Acad Sci U S A* 1998b;95:15043–8.
- Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Junien JL. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. *Behav Pharmacol* 1995;6:215–22.
- Brot MD, Koob GF, Britton KT. Anxiolytic effects of steroid hormones during the estrous cycle. Interactions with ethanol. *Recent Dev Alcohol* 1995;12:243–59.
- Caberlotto L, Fuxe K, Hurd YL. Characterization of NPY mRNA-expressing cells in the human brain: co-localization with Y2 but not Y1 mRNA in the cerebral cortex, hippocampus, amygdala, and striatum. *J Chem Neuroanat* 2000;20:327–37.
- Catzefflis C, Pierroz DD, Rohner-Jeanrenaud F, Rivier JE, Sizonenko PC, Aubert ML. Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and the somatotrophic axis in intact adult female rats. *Endocrinology* 1993;132:224–34.
- Chen S, Huang X, Zeng XJ, Sieghart W, Tietz EI. Benzodiazepine-mediated regulation of alpha1, alpha2, beta1-3 and gamma2 GABA(A) receptor subunit proteins in the rat brain hippocampus and cortex. *Neuroscience* 1999;93:33–44.
- Chronwall BM, Zukowska Z. Neuropeptide Y, ubiquitous and elusive. *Peptides* 2004;25:359–63.
- Chronwall BM, DiMaggio DA, Massari VJ, Pickel VM, Ruggiero DA, O'Donohue TL. The anatomy of neuropeptide-Y-containing neurons in rat brain. *Neuroscience* 1985;15:1159–81.
- Clark JT, Keaton AK, Sahu A, Kalra SP, Mahajan SC, Gudger JN. Neuropeptide Y (NPY) levels in alcoholic and food restricted male rats: implications for site selective function. *Regul Pept* 1998;75–76:335–45.
- Colmers WF, Bleakman D. Effects of neuropeptide Y on the electrical properties of neurons. *Trends Neurosci* 1994;17:373–9.
- Concas A, Mostallino MC, Porcu P, Follesa P, Barbaccia ML, Trabucchi M, et al. Role of brain allopregnanolone in the plasticity of gamma-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. *Proc Natl Acad Sci U S A* 1998;95:13284–9.
- Concha MG, Biggio G. Stress and GABAergic transmission: biochemical and behavioural studies. *Adv Biochem Psychopharmacol* 1986;41:121–36.
- Concha MG, Giorgi O, Gatta F, Biggio G. Long-lasting proconvulsant effect induced by chronic administration of the beta-carboline derivative FG 7142. *Neurosci Lett* 1985;62:237–40.
- Costa E, Guidotti A. Benzodiazepines on trial: a research strategy for their rehabilitation. *Trends Pharmacol Sci* 1996;17:192–200.
- Costa E, Guidotti A, Mao CC. Evidence for involvement of GABA in the action of benzodiazepines: studies on rat cerebellum. *Adv Biochem Psychopharmacol* 1975:113–30.
- Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. *Nature* 2001;411:480–4.
- cuna-Goycolea C, Tamamaki N, Yanagawa Y, Obata K, van den Pol AN. Mechanisms of neuropeptide Y, peptide YY, and pancreatic polypeptide inhibition of identified green fluorescent protein-expressing GABA neurons in the hypothalamic neuroendocrine arcuate nucleus. *J Neurosci* 2005;25:7406–19.
- de Lanerolle NC, Kim JH, Robbins RJ, Spencer DD. Hippocampal interneuron loss and plasticity in human temporal lobe epilepsy. *Brain Res* 1989;495:387–95.
- de Quidt ME, Emson PC. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system-II. Immunohistochemical analysis. *Neuroscience* 1986;18:545–618.
- Devaud LL, Purdy RH, Finn DA, Morrow AL. Sensitization of gamma-aminobutyric acidA receptors to neuroactive steroids in rats during ethanol withdrawal. *J Pharmacol Exp Ther* 1996;278:510–7.
- Devaud LL, Fritschy JM, Sieghart W, Morrow AL. Bidirectional alterations of GABA(A) receptor subunit peptide levels in rat cortex during chronic ethanol consumption and withdrawal. *J Neurochem* 1997;69:126–30.
- Dorow R, Horowski R, Paschelke G, Amin M. Severe anxiety induced by FG 7142, a betacarboline ligand for benzodiazepine receptors. *Lancet* 1983;2:98–9.
- Dumont Y, Martel JC, Fournier A, St-Pierre S, Quirion R. Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. *Prog Neurobiol* 1992;38:125–67.
- Dumont Y, Jacques D, Bouchard P, Quirion R. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. *J Comp Neurol* 1998;402:372–84.
- Ehlers CL, Somes C, Seifritz E, Rivier JE. CRF/NPY interactions: a potential role in sleep dysregulation in depression and anxiety. *Depress Anxiety* 1997;6:1–9.
- Ehlers CL, Li TK, Lumeng L, Hwang BH, Somes C, Jimenez P, et al. Neuropeptide Y levels in ethanol-naive alcohol-preferring and nonpreferring rats and in Wistar rats after ethanol exposure. *Alcohol Clin Exp Res* 1998;22:1778–82.



- Engel SR, Grant KA. Neurosteroids and behavior. *Int Rev Neurobiol* 2001;46:321–48.
- Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. *Nature* 1996;381:415–21.
- Eva C, Keinanen K, Monyer H, Seeburg P, Sprengel R. Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family. *FEBS Lett* 1990;271:81–4.
- Eva C, Oberto A, Sprengel R, Genazzani E. The murine NPY-1 receptor gene. Structure and delineation of tissue-specific expression. *FEBS Lett* 1992;314:285–8.
- Eva C, Serra M, Mele P, Panzica GC, Oberto A. Physiology and gene regulation of brain NPY Y1 receptor. *Front Neuroendocrinol*, submitted for publication.
- Ferrara G, Serra M, Zammaretti F, Pisu MG, Panzica GC, Biggio G, et al. Increased expression of the neuropeptide Y receptor Y(1) gene in the medial amygdala of transgenic mice induced by long-term treatment with progesterone or allopregnanolone. *J Neurochem* 2001;79:417–25.
- Finn DA, Ford MM, Wiren KM, Roselli CE, Crabbe JC. The role of pregnane neurosteroids in ethanol withdrawal: behavioral genetic approaches. *Pharmacol Ther* 2004;101:91–112.
- Follesa P, Floris S, Tuligi G, Mostallino MC, Concas A, Biggio G. Molecular and functional adaptation of the GABA(A) receptor complex during pregnancy and after delivery in the rat brain. *Eur J Neurosci* 1998;10:2905–12.
- Follesa P, Serra M, Cagetti E, Pisu MG, Porta S, Floris S, et al. Allopregnanolone synthesis in cerebellar granule cells: roles in regulation of GABA(A) receptor expression and function during progesterone treatment and withdrawal. *Mol Pharmacol* 2000;57:1262–70.
- Follesa P, Cagetti E, Mancuso L, Biggio F, Manca A, Maciocco E, et al. Increase in expression of the GABA(A) receptor alpha(4) subunit gene induced by withdrawal of, but not by long-term treatment with, benzodiazepine full or partial agonists. *Brain Res Mol Brain Res* 2001;92:138–48.
- Follesa P, Porcu P, Sogliano C, Cinus M, Biggio F, Mancuso L, et al. Changes in GABAA receptor gamma 2 subunit gene expression induced by long-term administration of oral contraceptives in rats. *Neuropharmacology* 2002;42:325–36.
- Follesa P, Biggio F, Talani G, Murru L, Serra M, Sanna E, et al. Neurosteroids, GABA(A) receptors, and ethanol dependence. *Psychopharmacology (Berl)* 2005;1–14.
- Gariboldi M, Conti M, Cavaleri D, Samanin R, Vezzani A. Anticonvulsant properties of BIBP3226, a non-peptide selective antagonist at neuropeptide Y Y1 receptors. *Eur J Neurosci* 1998;10:757–9.
- Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salvestrone C, Tonetti A, et al. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. *J Clin Endocrinol Metab* 1998;83:2099–103.
- Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, et al. A receptor subtype involved in neuropeptide-Y-induced food intake. *Nature* 1996;382:168–71.
- Glass MJ, Billington CJ, Levine AS. Opioids and food intake: distributed functional neural pathways? *Neuropeptides* 1999;33:360–8.
- Gorin RE, Crabbe JC, Tanchuck MA, Long SL, Finn DA. Effects of finasteride on chronic and acute ethanol withdrawal severity in the WSP and WSR selected lines. *Alcohol Clin Exp Res* 2005;29:939–48.
- Grobin AC, Matthews DB, Devaud LL, Morrow AL. The role of GABA(A) receptors in the acute and chronic effects of ethanol. *Psychopharmacology (Berl)* 1998;139:2–19.
- Guidotti A, Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability? *Biol Psychiatry* 1998;44:865–73.
- Gustafson EL, Card JP, Moore RY. Neuropeptide Y localization in the rat amygdaloid complex. *J Comp Neurol* 1986;251:349–62.
- Haefely W. Biological basis of drug-induced tolerance, rebound, and dependence. Contribution of recent research on benzodiazepines. *Pharmacopsychiatry* 1986;19:353–61.
- Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. *Nat Neurosci* 1998;1:271–2.
- Heilig M. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. *Regul Pept* 1995;59:201–5.
- Heilig M, Murison R. Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat. *Regul Pept* 1987;19:221–31.
- Heilig M, Soderpalm B, Engel JA, Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. *Psychopharmacology (Berl)* 1989;98:524–9.
- Heilig M, McLeod S, Koob GK, Britton KT. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. *Regul Pept* 1992;41:61–9.
- Heilig M, Koob GF, Ekman R, Britton KT. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. *Trends Neurosci* 1994;17:80–5.
- Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA. Cloned human neuropeptide Y receptor couples to two different second messenger systems. *Proc Natl Acad Sci U S A* 1992;89:5794–8.
- Hokfelt T, Broberger C, Zhang X, Diez M, Kopp J, Xu Z, et al. Neuropeptide Y: some viewpoints on a multifaceted peptide in the normal and diseased nervous system. *Brain Res Brain Res Rev* 1998;26:154–66.
- Horvath TL, Bechmann I, Naftolin F, Kalra SP, Leranath C. Heterogeneity in the neuropeptide Y-containing neurons of the rat arcuate nucleus: GABAergic and non-GABAergic subpopulations. *Brain Res* 1997;756:283–6.
- Horvath TL, Pu S, Dube MG, Diano S, Kalra SP. A GABA-neuropeptide Y (NPY) interplay in LH release. *Peptides* 2001;22:473–81.
- Howell OW, Scharfman HE, Herzog H, Sundstrom LE, Beck-Sickinger A, Gray WP. Neuropeptide Y is neuroproliferative for post-natal hippocampal precursor cells. *J Neurochem* 2003;86:646–59.
- Jinno S, Kosaka T. Patterns of expression of neuropeptides in GABAergic nonprincipal neurons in the mouse hippocampus: quantitative analysis with optical disector. *J Comp Neurol* 2003;461:333–49.
- Kalra SP, Crowley WR. Neuropeptide Y: a novel neuroendocrine peptide in the control of pituitary hormone secretion, and its relation to luteinizing hormone. *Front Neuroendocrinol* 1992;13:1–46.
- Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. *Proc Natl Acad Sci U S A* 1991;88:10931–5.
- Kalra SP, Fuentes M, Fournier A, Parker SL, Crowley WR. Involvement of the Y-1 receptor subtype in the regulation of luteinizing hormone secretion by neuropeptide Y in rats. *Endocrinology* 1992;130:3323–30.
- Kanatani A, Mashiko S, Murai N, Sugimoto N, Ito J, Fukuroda T, et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. *Endocrinology* 2000;141:1011–6.
- Kask A, Rago L, Harro J. Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam. *Eur J Pharmacol* 1996;317: R3–R4.
- Kask A, Rago L, Harro J. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226. *Br J Pharmacol* 1998;124:1507–15.
- Kask A, Nguyen HP, Pabst R, von HS. Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety. *Neuroscience* 2001;104:799–806.
- Khisti RT, Penland SN, VanDoren MJ, Grobin AC, Morrow AL. GABAergic neurosteroid modulation of ethanol actions. *World J Biol Psychiatry* 2002;3:87–95.
- Kinoshita H, Jessop DS, Finn DP, Coventry TL, Roberts DJ, Ameno K, et al. Acute ethanol decreases NPY mRNA but not POMC mRNA in the arcuate nucleus. *Neuroreport* 2000;11:3517–9.
- Kishi T, Aschkenasi CJ, Choi BJ, Lopez ME, Lee CE, Liu H, et al. Neuropeptide Y Y1 receptor mRNA in rodent brain: distribution and colocalization with melanocortin-4 receptor. *J Comp Neurol* 2005;482:217–43.
- Koob GF. Alcoholism: allostasis and beyond. *Alcohol Clin Exp Res* 2003;27:232–43.
- Koob GF, Roberts AJ, Schulteis G, Parsons LH, Heyser CJ, Hyttia P, et al. Neurocircuitry targets in ethanol reward and dependence. *Alcohol Clin Exp Res* 1998;22:3–9.

- Krause J, Eva C, Seeburg PH, Sprengel R. Neuropeptide Y1 subtype pharmacology of a recombinantly expressed neuropeptide receptor. *Mol Pharmacol* 1992;41:817–21.
- Krysiak R, Obuchowicz E, Herman ZS. Diazepam and buspirone alter neuropeptide Y-like immunoreactivity in rat brain. *Neuropeptides* 1999;33:542–9.
- Krysiak R, Obuchowicz E, Herman ZS. Conditioned fear-induced changes in neuropeptide Y-like immunoreactivity in rats: the effect of diazepam and buspirone. *Neuropeptides* 2000;34:148–57.
- Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, Nakamura M. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. *Proc Natl Acad Sci U S A* 1998;95:15659–64.
- Lambert JJ, Belelli D, Hamey SC, Peters JA, Frenguelli BG. Modulation of native and recombinant GABA(A) receptors by endogenous and synthetic neuroactive steroids. *Brain Res Brain Res Rev* 2001;37:68–80.
- Larhammar D, Salaneck E. Molecular evolution of NPY receptor subtypes. *Neuropeptides* 2004;38:141–51.
- Lundell I, Blomqvist AG, Berglund MM, Schober DA, Johnson D, Statnick MA, et al. Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. *J Biol Chem* 1995;270:29123–8.
- Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. *Science* 1986;232:1004–7.
- Mannon PJ, Mele JM. Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor. *Biochem J* 2000;350(Pt 3):655–61.
- McDonald AJ, Pearson JC. Coexistence of GABA and peptide immunoreactivity in non-pyramidal neurons of the basolateral amygdala. *Neurosci Lett* 1989;100:53–8.
- Mele P, Oberto A, Serra M, Pisu MG, Floris I, Biggio G, et al. Increased expression of the gene for the Y1 receptor of neuropeptide Y in the amygdala and paraventricular nucleus of Y1R/LacZ transgenic mice in response to restraint stress. *J Neurochem* 2004;89:1471–8.
- Mele P, Serra M, Collura D, Pisu MG, Biggio G and Eva C. Fluctuation in brain concentration of neuroactive steroids modulates NPY Y1 receptor signalling in the amygdala of transgenic mice during ethanol withdrawal. Submitted for publication.
- Mhatre MC, Ticku MK. Chronic ethanol administration alters gamma-aminobutyric acid receptor gene expression. *Mol Pharmacol* 1992;42:415–22.
- Mhatre M, Mehta AK, Ticku MK. Chronic ethanol administration increases the binding of the benzodiazepine inverse agonist and alcohol antagonist [3H] RO15-4513 in rat brain. *Eur J Pharmacol* 1988;153:141–5.
- Mhatre MC, Pena G, Sieghart W, Ticku MK. Antibodies specific for GABA A receptor alpha subunits reveal that chronic alcohol treatment down-regulates alpha-subunit expression in rat brain regions. *J Neurochem* 1993;61:1620–5.
- Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, et al. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. *Pharmacol Rev* 1998;50:143–50.
- Mikkelsen JD, Woldbye D, Kragh J, Larsen PJ, Bolwig TG. Electroconvulsive shocks increase the expression of neuropeptide Y (NPY) mRNA in the piriform cortex and the dentate gyrus. *Brain Res Mol Brain Res* 1994;23:317–22.
- Mikkelsen JD, Karle J, Madsen TM. Intrahippocampal infusion of antisense oligodeoxynucleotide to the GABA(A) receptor gamma2 subunit enhances neuropeptide Y gene expression. *Brain Res Bull* 2001;54:91–9.
- Moran MH, Smith SS. Progesterone withdrawal I: pro-convulsant effects. *Brain Res* 1998;807:84–90.
- Morrow AL, Montpied P, Lingford-Hughes A, Paul SM. Chronic ethanol and pentobarbital administration in the rat: effects on GABA A receptor function and expression in brain. *Alcohol* 1990;7:237–44.
- Morrow AL, Janis GC, VanDoren MJ, Matthews DB, Samson HH, Janak PH, et al. Neurosteroids mediate pharmacological effects of ethanol: a new mechanism of ethanol action? *Alcohol Clin Exp Res* 1999;23:1933–40.
- Morrow AL, VanDoren MJ, Penland SN, Matthews DB. The role of GABAergic neuroactive steroids in ethanol action, tolerance and dependence. *Brain Res Brain Res Rev* 2001;37:98–109.
- Mullins D, Kirby D, Hwa J, Guzzi M, Rivier J, Parker E. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity *in vivo*. *Mol Pharmacol* 2001;60:534–40.
- Naveilhan P, Canals JM, Valjakka A, Vartiainen J, Arenas E, Ernfors P. Neuropeptide Y alters sedation through a hypothalamic Y1-mediated mechanism. *Eur J Neurosci* 2001a;13:2241–6.
- Naveilhan P, Hassani H, Lucas G, Blakeman KH, Hao JX, Xu XJ, et al. Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. *Nature* 2001b;409:513–7.
- Nie M, Selbie LA. Neuropeptide Y Y1 and Y2 receptor-mediated stimulation of mitogen-activated protein kinase activity. *Regul Pept* 1998;75–76:207–13.
- Oberto A, Tolosano E, Brusa R, Altruda F, Panzica G, Eva C. The murine Y1 receptor 5' upstream sequence directs cell-specific and developmentally regulated LacZ expression in transgenic mice CNS. *Eur J Neurosci* 1998;10:3257–68.
- Oberto A, Panzica G, Altruda F, Eva C. Chronic modulation of the GABA(A) receptor complex regulates Y1 receptor gene expression in the medial amygdala of transgenic mice. *Neuropharmacology* 2000;39:227–34.
- Oberto A, Panzica GC, Altruda F, Eva C. GABAergic and NPY-Y(1) network in the medial amygdala: a neuroanatomical basis for their functional interaction. *Neuropharmacology* 2001;41:639–42.
- Oberto A, Serra M, Pisu MG, Biggio G, Eva C. Changes in expression of the neuropeptide Y Y1 receptor gene in the medial amygdala of transgenic mice during pregnancy and after delivery. *J Neurochem* 2002;82:1272–81.
- Olsen RW, Liang J, Cagetti E, Spigelman I. Plasticity of GABA A receptors in brains of rats treated with chronic intermittent ethanol. *Neurochem Res* 2005;30:1579–88.
- Ovesjo ML, Gamstedt M, Collin M, Meister B. GABAergic nature of hypothalamic leptin target neurons in the ventromedial arcuate nucleus. *J Neuroendocrinol* 2001;13:505–16.
- Pandey SC. Anxiety and alcohol abuse disorders: a common role for CREB and its target, the neuropeptide Y gene. [Review] [70 refs]. *Trends Pharmacol Sci* 2003;24:456–60.
- Pedrazzini T, Seydoux J, Kunstner P, Aubert JF, Grouzmann E, Beermann F, et al. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. *Nat Med* 1998;4:722–6.
- Pickel VM, Beck-Sickinger AG, Chan J, Weiland HA. Y1 receptors in the nucleus accumbens: ultrastructural localization and association with neuropeptide Y. *J Neurosci Res* 1998;52:54–68.
- Pronchuk N, Beck-Sickinger AG, Colmers WF. Multiple NPY receptors inhibit GABA(A) synaptic responses of rat medial parvocellular effector neurons in the hypothalamic paraventricular nucleus. *Endocrinology* 2002;143: 535–43.
- Pu S, Jain MR, Horvath TL, Diano S, Kalra PS, Kalra SP. Interactions between neuropeptide Y and gamma-aminobutyric acid in stimulation of feeding: a morphological and pharmacological analysis. *Endocrinology* 1999;140:933–40.
- Purdy RH, Morrow AL, Moore Jr PH, Paul SM. Stress-induced elevations of gammaaminobutyric acid type A receptor-active steroids in the rat brain. *Proc Natl Acad Sci U S A* 1991;88:4553–7.
- Raposo PD, Pierroz DD, Broqua P, White RB, Pedrazzini T, Aubert ML. Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. *Mol Cell Endocrinol* 2001;185:195–204.
- Reddy DS, Rogawski MA. Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA(A) receptor function and seizure susceptibility. *J Neurosci* 2002;22:3795–805.
- Rose PM, Fernandes P, Lynch JS, Frazier ST, Fisher SM, Kodukula K, et al. Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. *J Biol Chem* 1995;270:29038.
- Roy A, Pandey SC. The decreased cellular expression of neuropeptide Y protein in rat brain structures during ethanol withdrawal after chronic ethanol exposure. *Alcohol Clin Exp Res* 2002;26:796–803.

- Rupprecht R, di MF, Hermann B, Strohle A, Lancel M, Romeo E, et al. Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology. *Brain Res Brain Res Rev* 2001;37:59–67.
- Russ JC. The image processing handbook. CRC Press; 1995.
- Sajdyk TJ, Vandergriff MG, Gehlert DR. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. *Eur J Pharmacol* 1999;368:143–7.
- Sajdyk TJ, Shekhar A, Gehlert DR. Interactions between NPY and CRF in the amygdala to regulate emotionality. *Neuropeptides* 2004;38:225–34.
- Sanna E, Serra M, Cossu A, Colombo G, Follesa P, Cuccheddu T, et al. Chronic ethanol intoxication induces differential effects on GABAA and NMDA receptor function in the rat brain. *Alcohol Clin Exp Res* 1993;17:115–23.
- Sanna E, Mostallino MC, Busonero F, Talani G, Tranquilli S, Mameni M, et al. Changes in GABA(A) receptor gene expression associated with selective alterations in receptor function and pharmacology after ethanol withdrawal. *J Neurosci* 2003;23:11711–24.
- Sanna E, Talani G, Busonero F, Pisu MG, Purdy RH, Serra M, et al. Brain steroidogenesis mediates ethanol modulation of GABAA receptor activity in rat hippocampus. *J Neurosci* 2004;24:6521–30.
- Sato I, Arima H, Ozaki N, Watanabe M, Goto M, Hayashi M, et al. Insulin inhibits neuropeptide Y gene expression in the arcuate nucleus through GABAergic systems. *J Neurosci* 2005;25:8657–64.
- Schroeder JP, Olive F, Koenig H, Hodge CW. Intra-amygdala infusion of the NPY Y1 receptor antagonist BIBP 3226 attenuates operant ethanol self-administration. *Alcohol Clin Exp Res* 2003;27:1884–91.
- Serra M, Pisu MG, Floris I, Cara V, Purdy RH, Biggio G. Social isolation-induced increase in the sensitivity of rats to the steroidogenic effect of ethanol. *J Neurochem* 2003;85:257–63.
- Serra M, Mostallino MC, Talani G, Pisu MG, Carta M, Mura ML, et al. Social isolation-induced increase in  $\alpha 4$  and  $\delta$  subunits gene expression is associated with a greater efficacy of ethanol on steroidogenesis and GABAA receptor function. *J Neurochem* 2006;98:122–33.
- Sloviter RS. Calcium-binding protein (calbindin-D28k) and parvalbumin immunocytochemistry: localization in the rat hippocampus with specific reference to the selective vulnerability of hippocampal neurons to seizure activity. *J Comp Neurol* 1989;280:183–96.
- Sloviter RS. Permanently altered hippocampal structure, excitability, and inhibition after experimental status epilepticus in the rat: the “dormant basket cell” hypothesis and its possible relevance to temporal lobe epilepsy. *Hippocampus* 1991;1:41–66.
- Smith SS, Gong QH. Ethanol administration rapidly reverses  $\alpha 4$  GABAA receptor subunit upregulation following steroid exposure. *Neuropharmacology* 2004;47:9–16.
- Sparta DR, Fee JR, Hayes DM, Knapp DJ, MacNeil DJ, Thiele TE. Peripheral and central administration of a selective neuropeptide Y Y1 receptor antagonist suppresses ethanol intake by C57BL/6J mice. *Alcohol Clin Exp Res* 2004;28:1324–30.
- St-Pierre JA, Dumont Y, Nouel D, Herzog H, Hamel E, Quirion R. Preferential expression of the neuropeptide Y Y1 over the Y2 receptor subtype in cultured hippocampal neurons and cloning of the rat Y2 receptor. *Br J Pharmacol* 1998;123:183–94.
- St-Pierre JA, Nouel D, Dumont Y, Beaudet A, Quirion R. Association of neuropeptide Y Y1 receptors with glutamate-positive and NPY-positive neurons in rat hippocampal cultures. *Eur J Neurosci* 2000;12:1319–30.
- Starback P, Wraith A, Eriksson H, Larhammar D. Neuropeptide Y receptor gene y6: multiple deaths or resurrections? *Biochem Biophys Res Commun* 2000;277:264–9.
- Sullivan SD, Moenter SM. Gamma-aminobutyric acid neurons integrate and rapidly transmit permissive and inhibitory metabolic cues to gonadotropin-releasing hormone neurons. *Endocrinology* 2004;145:1194–202.
- Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. *Nature* 1982;296:659–60.
- Thiele TE, Badia-Elder NE. A role for neuropeptide Y in alcohol intake control: evidence from human and animal research. *Physiol Behav* 2003;79:95–101.
- Thiele TE, Marsh DJ, Ste ML, Bernstein IL, Palmiter RD. Ethanol consumption and resistance are inversely related to neuropeptide Y levels. *Nature* 1998;396:366–9.
- Thiele TE, Koh MT, Pedrazzini T. Voluntary alcohol consumption is controlled via the neuropeptide Y Y1 receptor. *J Neurosci* 2002;22:RC208.
- Thiele TE, Sparta DR, Hayes DM, Fee JR. A role for neuropeptide Y in neurobiological responses to ethanol and drugs of abuse. *Neuropeptides* 2004;38:235–43.
- Thorsell A, Svensson P, Wiklund L, Sommer W, Ekman R, Heilig M. Suppressed neuropeptide Y (NPY) mRNA in rat amygdala following restraint stress. *Regul Pept* 1998;75–76:247–54.
- Thorsell A, Carlsson K, Ekman R, Heilig M. Behavioral and endocrine adaptation, and upregulation of NPY expression in rat amygdala following repeated restraint stress. *Neuroreport* 1999;10:3003–7.
- Thorsell A, Michalkiewicz M, Dumont Y, Quirion R, Caberlotto L, Rimondini R, et al. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. *Proc Natl Acad Sci U S A* 2000;97:12852–7.
- VanDoren MJ, Matthews DB, Janis GC, Grobin AC, Devaud LL, Morrow AL. Neuroactive steroid 3 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-20-one modulates electrophysiological and behavioral actions of ethanol. *J Neurosci* 2000;20:1982–9.
- Vezzani A, Sperk G, Colmers WF. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. *Trends Neurosci* 1999;22:25–30.
- Vezzani A, Moneta D, Mule F, Ravizza T, Gobbi M, French-Mullen J. Plastic changes in neuropeptide Y receptor subtypes in experimental models of limbic seizures. *Epilepsia* 2000;41(Suppl 6):S115–21.
- Vezzani A, Michalkiewicz M, Michalkiewicz T, Moneta D, Ravizza T, Richichi C, et al. Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y. *Neuroscience* 2002;110:237–43.
- Wahlestedt C, Reis DJ. Neuropeptide Y-related peptides and their receptors—are the receptors potential therapeutic drug targets? *Annu Rev Pharmacol Toxicol* 1993;33:309–52.
- Wang M, Backstrom T, Sundstrom I, Wahlstrom G, Olsson T, Zhu D, et al. Neuroactive steroids and central nervous system disorders. *Int Rev Neurobiol* 2001;46:421–59.
- Weinberg DH, Sirinathsinghji DJ, Tan CP, Shiao LL, Morin N, Rigby MR, et al. Cloning and expression of a novel neuropeptide Y receptor. *J Biol Chem* 1996;271:16435–8.
- Wisialowski T, Parker R, Preston E, Sainsbury A, Kraegen E, Herzog H, et al. Adrenalectomy reduces neuropeptide Y-induced insulin release and NPY receptor expression in the rat ventromedial hypothalamus. *J Clin Invest* 2000;105:1253–9.
- Woldbye DP, Larsen PJ, Mikkelsen JD, Klemp K, Madsen TM, Bolwig TG. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. *Nat Med* 1997;3:761–4.
- Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. *Pharmacol Rev* 1992;44:151–347.
- Yamada K, Shibasaki T, Tsumori C, Imaki T, Hotta M, Wakabayashi I, et al. Neuropeptide Y reverses corticotropin-releasing hormone- and psychological stress-caused shortening of sodium pentobarbital-induced sleep in rats. *Brain Res* 1996Y;725:272–5.
- Zhang H, Pandey SC. Effects of PKA modulation on the expression of neuropeptide Y in rat amygdaloid structures during ethanol withdrawal. *Peptides* 2003;24:1397–402.
- Zhang LP, Wang L. Changes of brain neuropeptide Y and its receptors in rats with flurazepam tolerance and dependence. *Acta Pharmacol Sin* 2005;26:1290–6.